Blocking some T cells may unleash full power of immune system against cancer
Researchers have identified a way to restrict regulatory T-cell activity in tumor cells, which in turn can unleash other immune cells to attack tumors in cancer patients. The research is being published in the August 3 issue of the Proceedings of the National Academy of Sciences. Read More
Cytiva, Pall to invest $1.5B in biomanufacturing over next 2 years
Cytiva and Pall, both Danaher companies, will make major investments in manufacturing capacity and services at 13 sites around the globe supporting life science customers, totaling $1.5 billion over two years. Read More
5 ways to improve the biomanufacturing workforce in regenerative medicine
A national survey of regenerative medicine biomanufacturing has revealed gaps in the training of skilled technical workers. The group behind the survey has proposed five steps to improve workforce quality and recently published its recommendations in Stem Cells Translational Medicine. Read More
Cellares, Poseida partner on cell therapy manufacturing
Poseida Therapeutics has joined Cellares' Early Access Partnership Program to accelerate cell therapy manufacturing. The collaboration is expected to provide insight into CAR T workflows as well as other technologies. Read More
Oncolytic viruses move closer to becoming effective cancer therapies
Scientists are identifying key factors that aid in the effectiveness of oncolytic viruses during the treatment of cancers, which could lead to better immunotherapies and inform clinicians which patients might benefit from the treatment. Findings from a June 22 Nature Communications article point to the clinical relevance and underlying mechanisms of a novel anticancer treatment. Read More
CAR-NK cells hold promise for solid tumors
A new cancer immunotherapy that leverages the ability of natural killer (NK) cells to discriminate between cancer and normal cells has shown promise in solid tumors. The technology incorporates the cancer-targeting ability of chimeric antigen receptors (CARs), according to data published in iScience on June 25. Read More
New in vitro models offer effective way to study respiratory viruses
A new accessible and scalable protocol for manufacturing in vitro lung cell models could have applications in the development of new therapies for respiratory viral infections and drug toxicology studies on human lungs. Details about the protocol were published in Stem Cells on June 21. Read More
Personalized cell therapies offer hope for some of the toughest cancers
Complete with a long-term vision of developing a pipeline of oncology therapies that modulate the functional immune system, Sotio of the Czech Republic is breaking into the world of autologous immuno-oncology therapies. The company's goal is to eventually become a prominent European pharmaceutical firm, according to Radek Špíšek, PhD, CEO and founding scientist of Sotio, who spoke with ScienceBoard.net in a recent interview. Read More
Danaher to acquire Aldevron in deal valued at $9.6B
Danaher announced it has signed a deal to buy DNA and messenger RNA manufacturer Aldevron for approximately $9.6 billion. Aldevron will operate as a standalone company in Danaher's Life Sciences business segment and is expected to boost Danaher's activities in genomic medicine. Read More
New study untangles how proteins ensure efficient DNA repair
Scientists have untangled the function of proteins that block normal DNA repair processes and may permit unwanted cancer cell growth. New research published in Molecular Cell on June 7 details how the XRCC1 molecular scaffold protein works in tandem with the poly(ADP-ribose) polymerase DNA break-detection protein to ensure that genetic errors are efficiently corrected. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
